FDA Approves Two New Antibiotics for UTIs

Federal regulators recently authorized new intravenous and oral treatments for complicated urinary tract infections.

Updated on Oct. 26, 2026 in Diseases — General

Bold flat-color editorial illustration of two glass vials and a pipette, representing pharmaceutical approval, in a clean, high-contrast geometric style. — The FDA recently authorized two new antibiotic treatments to combat resistant bacterial infections, providing clinicians with vital new tools for treating complex urinary tract conditions. AI Illustration. Upload story photo >

Live Poll

Do you trust that newer medical treatments are generally safer than older, established options?

In June 2026, the FDA approved a new oral carbapenem for treating pyelonephritis in patients with limited alternatives. This follows the October 2025 approval of intravenous fosfomycin, an antibiotic indicated as an alternative for specific drug-resistant infections.

Why it matters

These approvals provide clinicians with new options for treating complicated urinary tract infections while managing antimicrobial resistance. The treatments aim to reduce reliance on existing therapies for resistant bacterial strains, including extended-spectrum beta-lactamase-producing Escherichia coli.

The FDA-approved intravenous fosfomycin regimen requires 18 grams daily for seven days, a course that includes 6 grams of daily sodium. Clinical data from the Zeus phase three trial established this drug as non-inferior to piperacillin-tazobactam.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.

The details

Intravenous fosfomycin serves as an alternative to linezolid or daptomycin for patients with vancomycin-resistant enterococcus. The oral carbapenem utilizes a four-times-daily dosing schedule, an adjustment made after initial testing showed weaker performance in elderly patients and those with specific resistant bacteria.

2022: Trial results found the oral carbapenem non-inferior to ertapenem.
October 2025: The FDA approved intravenous fosfomycin.
June 2026: The FDA approved the oral carbapenem.

Health Landscape

The Zeus phase three trial established a new standard for comparing efficacy in antibiotic development, marking a shift in how federal regulators evaluate non-inferiority for urinary tract infection treatments. These approvals extend that research framework to address gaps in treating resistant infections.

Patients with pyelonephritis or limited oral antibiotic options may now access new, FDA-approved medications through their healthcare providers. These treatments provide specific alternatives for those battling resistant bacterial strains, potentially simplifying regimens that previously required inpatient intravenous care.

The takeaway

These antibiotic approvals expand the toolkit available for managing complex, drug-resistant bacterial infections. Clinicians are currently evaluating how the specific dosing requirements and sodium content of these new drugs will fit into existing patient safety protocols.